课题基金 / 基金详情

HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma

HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma
HHSN261201200021I/HHSN26100007癌症预防试剂的临床前体外和体内开发测定。
批准号:
8945265
负责人:
CLINTON GRUBBS
金额:
$54.51万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-12 至 2016-09-11

项目摘要

项目成果

CLINTON GRUBBS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This contract is to assess the new third-generation SERM, Bazedoxifene, alone and in combination with CE and/or an AI, to prevent mammary carcinogenesis induced in virgin female Sprague-Dawley rats by N-methyl-N-nitrosourea (MNU). The tasks will involve optimizing the dose and timing of BZA administration, and PK profile of BZA in combination with the AI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TASK ORDER: EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER
FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION
海外基金